Outcomes following neoadjuvant chemotherapy for breast cancer
Association of Breast Surgery ePoster Library. McLean R. 05/13/19; 257137; P093
Mr. Ross McLean
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P093
Topic: Non surgical treatments
Introduction: Chemotherapy in the neoadjuvant setting (NAC) prior to definitive surgery is well established, and can serve a number of valuable purposes, from downstaging the tumour to facilitating dual-anti HER2 treatment. This study aims to evaluate downstaging of the breast disease in a large dual-centre series. Methods Retrospective data collection from two breast screening institutions of all patients undergoing neoadjuvant chemotherapy from May 2014 to November 2017. Results: A total of 174 patients underwent neoadjuvant chemotherapy over the study period. Table 1 shows pathological respose rates categorised by receptor status. 91 patients (52%) underwent NAC with the intention of downstaging the tumour to permit breast conserving surgery (BCS); this was successful in 67 (74%) patients. Table 1: Pathological Response Breast, n(%)Hormonal Receptor StatuspCRpPRNo ResponseProgressionTotalER-,HER2-15 (31.9)28 (59.6)4 (8.5)0 (0.0)47 (27.0)ER-,HER2+21 (52.5)16 (40.0)0 (0.0)3 (7.5)40 (23.0)ER+, HER2-3 (10.3)21 (72.4)4 (13.8)1 (3.4)29 (16.7)ER+,HER2+22 (37.9)33 (56.9)2 (3.4)1 (1.7)58 (33.3)Total61 (35.1)98 (56.3)10 (5.7)
Topic: Non surgical treatments
Introduction: Chemotherapy in the neoadjuvant setting (NAC) prior to definitive surgery is well established, and can serve a number of valuable purposes, from downstaging the tumour to facilitating dual-anti HER2 treatment. This study aims to evaluate downstaging of the breast disease in a large dual-centre series. Methods Retrospective data collection from two breast screening institutions of all patients undergoing neoadjuvant chemotherapy from May 2014 to November 2017. Results: A total of 174 patients underwent neoadjuvant chemotherapy over the study period. Table 1 shows pathological respose rates categorised by receptor status. 91 patients (52%) underwent NAC with the intention of downstaging the tumour to permit breast conserving surgery (BCS); this was successful in 67 (74%) patients. Table 1: Pathological Response Breast, n(%)Hormonal Receptor StatuspCRpPRNo ResponseProgressionTotalER-,HER2-15 (31.9)28 (59.6)4 (8.5)0 (0.0)47 (27.0)ER-,HER2+21 (52.5)16 (40.0)0 (0.0)3 (7.5)40 (23.0)ER+, HER2-3 (10.3)21 (72.4)4 (13.8)1 (3.4)29 (16.7)ER+,HER2+22 (37.9)33 (56.9)2 (3.4)1 (1.7)58 (33.3)Total61 (35.1)98 (56.3)10 (5.7)
P093
Topic: Non surgical treatments
Introduction: Chemotherapy in the neoadjuvant setting (NAC) prior to definitive surgery is well established, and can serve a number of valuable purposes, from downstaging the tumour to facilitating dual-anti HER2 treatment. This study aims to evaluate downstaging of the breast disease in a large dual-centre series. Methods Retrospective data collection from two breast screening institutions of all patients undergoing neoadjuvant chemotherapy from May 2014 to November 2017. Results: A total of 174 patients underwent neoadjuvant chemotherapy over the study period. Table 1 shows pathological respose rates categorised by receptor status. 91 patients (52%) underwent NAC with the intention of downstaging the tumour to permit breast conserving surgery (BCS); this was successful in 67 (74%) patients. Table 1: Pathological Response Breast, n(%)Hormonal Receptor StatuspCRpPRNo ResponseProgressionTotalER-,HER2-15 (31.9)28 (59.6)4 (8.5)0 (0.0)47 (27.0)ER-,HER2+21 (52.5)16 (40.0)0 (0.0)3 (7.5)40 (23.0)ER+, HER2-3 (10.3)21 (72.4)4 (13.8)1 (3.4)29 (16.7)ER+,HER2+22 (37.9)33 (56.9)2 (3.4)1 (1.7)58 (33.3)Total61 (35.1)98 (56.3)10 (5.7)
Topic: Non surgical treatments
Introduction: Chemotherapy in the neoadjuvant setting (NAC) prior to definitive surgery is well established, and can serve a number of valuable purposes, from downstaging the tumour to facilitating dual-anti HER2 treatment. This study aims to evaluate downstaging of the breast disease in a large dual-centre series. Methods Retrospective data collection from two breast screening institutions of all patients undergoing neoadjuvant chemotherapy from May 2014 to November 2017. Results: A total of 174 patients underwent neoadjuvant chemotherapy over the study period. Table 1 shows pathological respose rates categorised by receptor status. 91 patients (52%) underwent NAC with the intention of downstaging the tumour to permit breast conserving surgery (BCS); this was successful in 67 (74%) patients. Table 1: Pathological Response Breast, n(%)Hormonal Receptor StatuspCRpPRNo ResponseProgressionTotalER-,HER2-15 (31.9)28 (59.6)4 (8.5)0 (0.0)47 (27.0)ER-,HER2+21 (52.5)16 (40.0)0 (0.0)3 (7.5)40 (23.0)ER+, HER2-3 (10.3)21 (72.4)4 (13.8)1 (3.4)29 (16.7)ER+,HER2+22 (37.9)33 (56.9)2 (3.4)1 (1.7)58 (33.3)Total61 (35.1)98 (56.3)10 (5.7)
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}